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Abstract
Background—ADC as a marker of tumor cellularity has been promising for evaluating response 
to therapy in patients with glioblastoma (GBM), but does not successfully stratify patients 
according to outcomes, especially in the up-front setting. Here we investigate if restriction 
spectrum imaging (RSI) an advanced diffusion imaging model, obtained after surgery but prior to 
radiation therapy (RT) could improve risk stratification in patients with newly-diagnosed GBM 
relative to ADC.
Methods—Pre-RT diffusion weighted and structural imaging of 40 patients with GBM were 
examined retrospectively. RSI and ADC based hyper-cellularity volume fractions (RSI-FLAIRvf, 
RSI-CEvf, ADC-FLAIRvf, ADC-CEvf) and intensities (RSI-FLAIR90%, RSI-CE90%, ADC-
FLAIR10%, ADC-CE10%) within the contrast enhancement (CE) and FLAIR hyper-intensity (HI) 
VOIs were calculated. The association of diffusion imaging metrics, CE volume (CEvol) and 
FLAIR-HI volume (FLAIRvol) with progression-free survival (PFS) and overall survival (OS) 
were evaluated using Cox proportional hazard (CPH) models.
Results—Among the diffusion metrics, RSI-FLAIRvf was the strongest prognostic metric of PFS 
(p=0.036) and OS (p=0.007) in a multivariate CPH analysis, with higher values indicating earlier 
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progression and shorter survival. RSI-FLAIR90% was also associated with OS (p=0.043) with 
higher intensities indicating shorter survival. None of the ADC metrics were associated with 
PFS/OS. CEvol exhibited a trend towards significance for OS (p=0.063).
Conclusions—RSI derived cellularity in FLAIR-HI regions may be a more robust prognostic 
marker than ADC and conventional imaging for early progression and poorer survival in GBM 
patients. However future studies with larger samples are needed to explore its predictive ability.
Introduction
Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor. 
Unfortunately, there has been only incremental improvement in the 5-year survival rate in 
the past decade (1). The standard of care for newly-diagnosed GBM remains fairly uniform 
with maximal permissible surgical resection followed by radiotherapy (RT) with concurrent 
and adjuvant temozolomide (TMZ) (2). Currently, novel molecular and cellular targeted 
therapies for treating GBMs are being investigated with many of them now in phase II 
clinical trials (3). With the advent of these new therapies, and a recent study showing that 
radiation dose escalation to 75Gy (above the standard dose of 60Gy) is safe and possibly 
more effective in newly diagnosed GBM (4), stratification of patients at highest risk for early 
progression is imperative as more aggressive or experimental treatments may be pursued in 
these individuals. These treatment decisions are usually considered within the first several 
weeks post-surgery once any residual tumor has been identified, making the pre-RT imaging 
pivotal for guiding the course of treatment.
Conventional MRI, including T1-post contrast and FLAIR, are non-specific as the former 
represents the breakdown of the blood-barrier due to tumor and non-tumor related causes 
and the latter may represent tumor-related edema, post-radiation change, or any cause of 
gliosis. Advanced MRI techniques, such as DWI, may offer more specific information 
related to the underlying physiology of the tissue and may complement existing measures. 
ADC estimates the magnitude of water diffusion in relation to the physical barriers in its 
environment. It is frequently used as an imaging biomarker for tumor cellularity (5,6) and is 
inversely correlated with tumor cell density (7). However, it is important to note that at the 
typical b-values used clinically (b=0,1000 s/mm2), the diffusion signal primarily arises from 
the extracellular space (8). Therefore, in addition to estimating cell density, the ADC 
calculated at these b-values is also influenced by factors such as edema and necrosis, 
subsequently making ADC a rather non-specific measure of tumor cellularity.
To account for the influence of edema and necrosis on ADC intensities in the tumor and 
peritumoral regions, histogram analysis of normalized ADC intensities (9,10) (nADC; 
normalized with respect to mean ADC in normal appearing white matter) and two Gaussian 
mixture modeling of the ADC intensities within the tumor (5,6) have been proposed. 
However, these statistical methods only seek to reclassify voxels within an ROI such that 
voxels with presumably solid tumor are included in the analysis while potentially 
problematic voxels that are confounded by partial voluming with edema and necrosis are 
removed. These methods have shown some promise for evaluating treatment response and 
predicting progression-free survival (PFS) in both the upfront (5,11) and recurrent (6,12) 
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setting following treatment with anti-angiogenic therapy. However, the utility of these ADC 
metrics for predicting response to standard chemoradiation has been less frequently 
explored. There is some data to suggest that although ADC intensities are not predictive of 
PFS or overall survival (OS) in the up-front setting (5,10), the volume of ADC with a large 
tumor burden (nADC<1.5; hyper-cellularity (HC) volume) within the T2 volume stratifies 
OS both pre (13) and post-surgery (9). But it is unclear if the hyper-cellularity (HC) volume 
was correlated with the underlying T2 volume and if its predictive value merely reflects the 
association of the T2 volume with survival. Multiple studies have used the increase or 
decrease of HC volume fraction (i.e., the HC volume defined with respect to the variation in 
a mixture of normal appearing white and gray matter) as a predictive marker for evaluating 
treatment response (14) since this metric may capture the percentage of the tumor that is 
highly cellular and is not correlated with the structural volumes. But the utility of HC 
volume fraction at individual time-points for early risk stratification has not been explored.
Multi-compartment models of diffusion based on advanced multi-shell acquisitions can 
provide a more straightforward approach for mitigating the confounding effects of edema 
and necrosis at the voxel level. In particular, restriction spectrum imaging (RSI) is an 
advanced diffusion imaging model that separates the relative contributions of hindered and 
restricted signals originating from extracellular and intracellular water compartments, 
respectively, using a multi-b-shell acquisition in conjunction with a linear mixture model 
(15–17). Furthermore, RSI incorporates geometrical information to disambiguate isotropic 
restricted diffusion in tumor cells from anisotropic restricted diffusion in elongated neuronal 
processes (axons/dendrites collectively called neurites). Previous studies have demonstrated 
the increased sensitivity and specificity of RSI over ADC and DWI in both brain tumors (18) 
and prostate cancer (19), and McDonald et al. have recently demonstrated that RSI 
cellularity is a stronger predictor of both PFS and OS in patients following treatment with 
bevacizumab relative to ADC (20). However, its utility for predicting survival in patients 
newly-diagnosed with GBM has not been explored.
Here we investigate the application of RSI for risk stratification in newly diagnosed, resected 
GBM. Our hypothesis is that RSI, due to its multi-b shell acquisition and its inherent ability 
to decouple diffusion signal within tumor cells from that of extracellular pathology (e.g., 
edema), would be a more robust marker of patient outcomes.
Materials and methods
This institutional review board approved retrospective study included 45 patients with 
pathologically-confirmed primary GBM who had pre-RT MRIs (median 23 days; range 9–
113 days from surgery and median 10 days; range 1–29 days before start of RT) that 
included standardized RSI and conventional imaging sequences acquired between January 
2011 and Nov 2015. All patients were followed for at least 6 months (May 2016). Patient 
characteristics are shown in Table 1. PFS and OS were defined relative to the pre-RT scan. 
All scans were reviewed by a neuro-radiologist to ensure image quality and determine the 
basis for exclusion. Of the 45 eligible candidates: 17 patients underwent a second resection 
with histopathology confirming tumor in 14 and showing predominantly radiation necrosis 
in 3. Given the expected bias that would be introduced in the calculation of PFS and OS by 
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including patients with pathologically proven radiation necrosis, these 3 patients were 
excluded. The two patients who were excluded had a GTR with marked FLAIR hyper-
intensity within the surgical cavity (presumed to be blood products or proteinaceous 
material) with associated high RSI and low ADC signal, which essentially masked any 
usable diffusion signal at the margins of the surgical cavity. Tumor progression was 
determined based on consensus between the treating neuro-oncologist and neuro-radiologist 
using the Response Assessment in Neuro Oncology (RANO) criteria (21). In the case of no 
progression or death, PFS was censored at the date of last stable imaging and OS was 
censored at the date of last contact.
MRI acquisition and Image pre-processing
MRI was performed on a 3.0T GE Signa Excite HDx scanner equipped with an 8-channel 
head coil. The imaging protocol included pre- and post-Gadolinium 3D volumetric T1-
weighted IR-SPGR sequences (TE/TR = 2.8/6.5ms; TI = 450ms; FA = 8°; FOV = 24cm; 
0.93 × 0.93 × 1.2 mm) and a 3D T2-weighted FLAIR sequence (TE/TR = 126/6000ms; TI = 
1863ms; FOV = 24cm; 0.93 × 0.93 × 1.2mm). For RSI, a single-shot pulsed-field gradient 
spin-echo (PGSE) EPI sequence was used (TE/TR = 96ms/17s; FOV = 24cm, matrix = 
96×96×48, 2.5mm voxel size) with 4 b-values (b = 0, 500, 1500, and 4000 s/mm2), and 6, 6, 
and 15 unique diffusion directions for each non-zero b-value, respectively (~8 min scan 
time). Prior to analysis, raw data were corrected for geometric distortions due to 
susceptibility, gradient nonlinearities, and eddy currents (22). This was followed by 
correction of patient motion and rigid registration of the pre- and post-contrast 3D IR-SPGR 
images and the FLAIR images to each other using in-house software. The diffusion-maps 
were registered to the post-contrast images through the B0 images (b=0mm2/s volume), 
which were registered to the FLAIR images.
ADC values were calculated from a tensor fit to the b = 0, 500 and 1500s/mm2 data. 
Technical details of the RSI mathematical framework are described in their entirety 
elsewhere (15–17) and the model used has been applied in other recent publication (20). 
Briefly, the measured signal in each voxel was modeled as the sum of signals from four 
distinct tissue compartments: 1) the signal from water trapped within small spherical cells 
that is restricted in all directions, 2) the signal from water trapped in elongated neuronal 
processes (i.e. neurites) that is restricted in the transverse direction, 3) the signal from 
extracellular water that is hindered by cells and neuronal processes, and 4) the signal from 
free water residing in CSF-filled compartments. RSI “cellularity” estimates were computed 
by combining the signal fraction from the intracellular compartment [1] with the isotropic 
restricted component of the neurite compartment [2]. The RSI cellularity maps were finally 
transformed to a standard z-score by scaling each patient’s data by the population mean and 
standard deviation in normal appearing white matter of all patients in this study.
VOIs
CE volumes (CEvol) and FLAIR hyper-intensity (FLAIR-HI) volumes (FLAIRvol) excluding 
the resection cavity and intrinsically T1 hyper-intense regions (i.e., post-surgical blood 
products) were segmented semi-automatically (Amira® software package, Visage Imaging, 
Inc.) on the co-registered post-contrast 3D IR-SPGR images and FLAIR images by a single 
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expert image analyst with 8 years of experience. For patients whose pre-RT scan was 
acquired within two weeks after surgery, the immediate post-surgery scan was used to 
exclude areas of restricted diffusion caused by resection-induced cytotoxic edema.
Imaging metrics
In this study, we chose to evaluate the utility of both the HC intensities and HC volume 
fractions as prognostic factors of PFS and OS. Based on a recent study (19), the 90th 
percentile of RSI cellularity values was selected for our analysis and the HC volume fraction 
was defined as the volume having an RSI cellularity Z score ≥ 1.5 within the CE and 
FLAIR-HI VOIs as the HC volume estimated with this pre-RT nADC threshold was 
successful in stratifying survival (9). Imaging metrics included in the analysis were the 
following: FLAIRvol, CEvol, the 90th percentile of RSI cellularity values in the CE (RSI-
CE90%) and in the FLAIR-HI (RSI-FLAIR90%) VOIs and the RSI based HC volume fraction 
in the CE (RSI-CEvf) and FLAIR-HI (RSI-FLAIRvf) VOIs. The following ADC metrics 
were estimated for comparing against the respective RSI metrics: the 10th percentile of ADC 
(11) in the CE (ADC-CE10%) and in the FLAIR-HI (ADC-FLAIR10%) VOIs, and the ADC 
based HC volume fraction [ADC Z score ≤ 1.5] in the CE (ADC-CEvf) and FLAIR-HI 
(ADC-FLAIRvf) VOIs.
Statistical Analysis
Univariate Cox Proportional Hazard (CPH) models were used to determine the contribution 
of resection type (STR – sub-total resection; GTR – gross total resection), age and gender to 
PFS and OS. Multivariate CPH models that included a single imaging metric combined with 
any significant clinical covariates were used to determine the relationship between each 
continuous pre-RT imaging metric and PFS/OS. Kaplan-Meier (KM) curves for the imaging 
metrics that were significant in the multivariate CPH models were obtained by 
dichotomizing the population based on their median value and were compared using a log-
rank test. Due to the exploratory nature of the study, we did not control for type I error. P 
values < 0.05 were considered statistically significant (R3.2.2). Statistical analysis was 
performed using R version 3.2.2 (23)
Results
Clinical
Median PFS in the final cohort (N=40) was 8.4 months and median OS was 19.5 months. 
Nine patients progressed within 6 months, 24 patients progressed within 12 months, 30 
patients progressed within 18 months and 33 patients progressed within 24 months. The 
results of univariate CPH analyses for the clinical and imaging metrics are summarized in 
Table 2. CPH models revealed that the resection type (STR-1 vs GTR-2) had a trend towards 
significance for PFS and was significant for OS (Table 2), hence it was included as a 
covariate in multivariate CPH analyses. Age and gender (male-1, female-2) were not 
predictive of PFS or OS in this cohort. Box plots of the imaging metrics are displayed in 
Figure 1 and the box plots split by the median PFS and OS excluding the values from the 
censored patients for the relevant metrics that achieved significance in Table 2 are displayed 
in supplementary Fig 1.
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CE and FLAIR-HI volumes
In a univariate CPH analysis, CEvol was significantly associated with PFS and OS (Table 2). 
When adjusted for resection type, CEvol was no longer significant for PFS and had a trend 
towards significance for OS (p=0.063; Table 3). The KM curves of the two groups obtained 
by a median split and compared using log-rank test were significantly different for PFS 
(χ2(1) =4.7, p=0.029) but not for OS (χ2(1) =3.1, p=0.078; Figure 2). Based on this 
stratification, the median PFS for the two groups was 218 and 338.5 days. FLAIRvol was not 
associated with PFS or OS.
RSI and ADC metrics
In a multivariate CPH analysis, RSI-FLAIR90% was significantly associated with OS 
(p=0.043) such that higher RSI intensities were associated with shorter survival (Table 3) 
and RSI-FLAIRvf was significantly associated with both PFS (p=0.036) and OS (p=0.007; 
Table 3) such that higher HC volume fractions were associated with earlier progression and 
shorter survival. None of the RSI metrics in the CE VOI were significant for PFS/OS.
The KM curves of the two groups obtained by a median split of RSI-FLAIRvf were 
significantly different for both PFS (χ2(1) =6.1, p=0.013) and OS (χ2(1) =7.7, p=0.005; 
Figure 2). The median PFS of the two groups was 201.5 and 367.5 days and the median OS 
of the two groups was 451 and 750.5 days. Despite a strong trend, stratification by the 
median RSI-FLAIR90% did not yield significant group differences in PFS (χ2(1) =2.8, 
p=0.095) and OS (χ2(1) =3.4, p=0.065).
To understand the influence of the threshold for defining HC volume fraction on the 
prognostic value, we repeated the analysis with HC volume fraction defined with a threshold 
of RSI cellularity Z score ≥ 1 and ≥ 2. RSI-FLAIRvf at Z≥ 1 was significantly associated 
with PFS (p=0.03; HR=1.023) and OS (p=0.042; HR=1.027). While RSI-FLAIRvf at Z≥ 2 
was significant for OS (p=0.009; HR=1.096), it was not significant for PFS (p=0.09; HR= 
1.043). Similarly, we also explored the prognostic value of the absolute HC volume with 
Z≥1.5 and they were prognostic for OS (HCvol in CE: p=0.018, HR=1.543; FLAIR-HI: 
p=0.042, HR=1.262) in a multivariate CPH analysis. HCvol within CE was significant for 
PFS in a univariate analysis (p=0.025; HR=1.141) but was not significant in a multivariate 
analysis with resection type as a covariate.
In a univariate CPH analysis, none of the ADC metrics were associated with PFS (Table 2). 
The absolute ADC HC volumes with Z≤1.5 within the FLAIR-HI VOI was significantly 
prognostic of OS in a univariate CPH analysis (p=0.015; HR=58.89) but only had a trend 
towards significance (p=0.079; HR=20.06) after accounting for resection type in a 
multivariate CPH analysis and was not associated with PFS (univariate: p=0.138; 
HR=4.835). The ADC HC volumes within CE VOI were not associated with outcomes.
Representative images of two patients in this cohort with short (patient A) and long (patient 
B) PFS are shown in Figure 3. Patient A had lower CEvol, FLAIRvol and ADC-FLAIR10% 
but higher RSI-FLAIR90%, RSI-FLAIRvf and ADC-FLAIRvf than patient B, likely reflecting 
higher tumor cellularity in patient’s FLAIR-HI region. RSI-cellularity maps exhibit greater 
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conspicuity in this region compared to ADC maps. Accordingly, patientA had shorter PFS 
and OS compared to patientB.
Discussion
In the management of a highly aggressive tumor like GBM, the ability to stratify patient 
survival post-operatively is important as this information can directly impact therapeutic 
decision-making. In this study, we found RSI metrics to better stratify patients according to 
both PFS and OS compared to conventional imaging and ADC metrics. Unfortunately, CEvol 
and FLAIRvol may have limited prognostic value in this setting once the extent of the 
resection is considered. Glioblastoma patients often have a more infiltrative tumor pattern 
and possibly a more hypoxic tumor biology (24) with some of them responding poorly to 
radiotherapy or conventional chemotherapy (25). The non-specificity of these conventional 
metrics could potentially be due to the hypoxic tumors not having contrast enhancement and 
the presence of infiltrative tumors not having a noticeable signal in both T1 and T2 images. 
Hence, there is a need for better imaging metrics that perform reliably and may aid in 
identification of GBM patients at high risk for early recurrence and worse survival.
Among the imaging metrics, we found that the pre-RT RSI derived measures of cellularity 
within the FLAIR-HI region were associated with PFS and OS. The prognostic value of RSI 
appeared robust to the threshold used to determine the HC volume. Conversely, ADC 
metrics within the FLAIR-HI region were not associated with outcomes. Tumor progression 
results in areas of increased tumor cellularity (i.e., decrease in diffusivity) and also areas of 
increased edema (i.e., increase in diffusivity), both of which can occur simultaneously 
within an imaging voxel. Furthermore, post-surgery but pre-RT, a significant portion of the 
enhancing HC volume of the tumor has probably been resected and the residual HC tumor is 
interspersed with edema. As ADC is a composite measure, the effects of these two opposing 
factors may cancel each other out, therefore limiting the prognostic value of ADC. RSI 
overcomes this limitation by separating the diffusivities associated with intracellular, 
restricted diffusion from the extracellular effects of edema. In contrast to a previous study 
(9) the absolute ADC HC volume was not significantly associated with OS and this might be 
due to the inclusion of resection type as a covariate in the analysis. Even though the absolute 
RSI HC volume was prognostic of OS, the volume fraction was a stronger prognostic metric 
of PFS/OS. We did not find an association between any of our diffusion metrics in the CE 
region similar to that of previous studies (9,10). Although the reason for this is not clear, it is 
likely that the CE region was quite limited in size in most patients given the short interval 
between surgery and RT.
It is worth noting that other advanced imaging techniques, including perfusion (10), MR 
spectroscopic imaging (MRSI) (26) and PET (27) have also been shown to stratify outcomes 
in GBM patients. While perfusion imaging provides information on vascular density and 
flow, MRSI and PET provide metabolic information. Pre-RT perfusion imaging metrics have 
been shown to predict PFS (10) but perfusion is limited in the central core of a solid tumor 
with hypoxic cancer cells (28) and with anti-angiogenic therapy where the vasculature is 
normalized removing the leaky vessels in the tumor (29). Pre RT MRSI metrics are 
associated with both PFS and OS (26) but suffer from lower spatial resolution compared to 
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conventional, perfusion and diffusion MRI. Although diffusion metrics should perform 
better than perfusion and MRSI with hypoxic tumor and anti-angiogenic therapy, none of the 
previous studies have shown an association of pre-RT diffusion with outcomes. Here we 
show that RSI based cellularity is a prognostic metric of PFS and OS and may offer 
advantages over perfusion and MRSI in the pre-RT setting.
One of the main limitations of the current study is the small sample size obtained at a single 
institution. The current study represents our effort to explore the clinical utility of RSI in a 
highly controlled study where all the patients were scanned in the same scanner and all 
images were processed in a highly uniform manner that included robust corrections for 
motion and geometric distortions. Given our modest size, we might be underpowered to 
detect smaller associations between some of our imaging metrics and survival. The 
generalizability and reproducibility of our results will need to be tested in prospective, multi-
site clinical trials across multiple vendor platforms. A second limitation is that the 
heterogeneity of the therapeutic approaches that each patient received following standard RT 
and TMZ made it difficult to stratify patients according to treatment regimen. However, our 
major finding is that RSI performed better than ADC and conventional imaging in the same 
patient cohort, which is not confounded by between patient treatment variance. Future 
studies with cohorts large enough to stratify patients according to the additional therapies 
received would be of great benefit for better delineating predictors of response to various 
therapies. Another possible limitation is that the tumors were segmented by a single imaging 
expert. Thus, intra and inter-observer variability of the tumor segmentations were not 
evaluated. In addition, although all patients had pathology confirmed GBMs at the outset, 
histological validation of tumor progression was not available for all patients. Furthermore, 
correlation with genomic information and molecular markers (such as MGMT and IDH 
status), which are known to provide prognostic information, could not be performed as these 
data were only available for a subset of the cohort (Table 1). Molecular information is now 
systematically collected for GBM patients at our institution facilitating future studies 
investigating the prognostic value of these markers. Although the results from our recent 
preclinical study [30] show that the RSI cellularity metric correlates with histopathological 
markers of cellularity, additional validation in GBM patients is warranted.
Conclusion
Following surgery but prior to initiating RT, RSI derived cellularity in the FLAIR-HI region 
performs better than ADC and conventional imaging for risk stratification in GBM patients. 
Therefore, RSI could be potentially useful for identifying patients at highest risk for early 
progression and shorter survival. However, future studies with larger sample sizes are 
needed to explore its predictive ability.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. 
Boxplots of the imaging metrics.
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Fig 2. 
Kaplan-Meier curves for the cohort stratified based on the median values for RSI-FLAIRvf 
for PFS [a] and OS [c]; and CEvol for PFS [b] and OS [d].
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Fig 3. 
Shown here are the axial T1 post, FLAIR, ADC and RSI-cellularity Z-score maps acquired 
post-surgery but pre-RT for two patients A and B. The VOI contours are shown in red and 
green for the CE and FLAIR-HI respectively. Patient A is a 63-year male with right posterior 
frontal GBM who underwent STR. This patient had high RSI cellularity in the FLAIR-HI 
region. Although there is corresponding ADC hypo-intensity in this region, it is subtle and 
inconspicuous. He had a shorter PFS and OS (PFS-4.2, OS-6.6 months) than Patient B. 
Patient B is a 31-year female with a right frontal GBM. There are no areas of high RSI 
cellularity or low ADC signal in the FLAIR-HI or CE region. He had a correspondingly 
longer PFS (PFS-14.5, OS-19.9 months).
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Table 1
Patient characteristics
Resection typea STR (n=22); GTR (n=18)
Sex 24 – male; 16 - female
Age: median [range] in yrs 58 [31–84]
PFS: median [range] in months 8.42 [3.5 – 50.53]; 7 censored
OS: median [range] in months 19.48 [6.37–50.93]; 8 censored
Bevacizumab at recurrence 17 patients
MGMT status 12-unmethylated, 8-methylated, 20-unknown
IDH status 15-WTb, 25 - unknown
EGFR amplification 7-unamplified, 12-amplified, 21-unknown
EGFRVIII status 12-positive, 9-negative, 19-unknown
a
Resection type was determined from the immediate post-surgical scan acquired within 48 hours of surgery for all patients that included both T1-
post contrast and FLAIR sequences.
bWT – wild type
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Table 2
Results of univariate CPH analyses of the continuous clinical imaging metrics
Metrics PFS OS
p value HR [95% CI] p value HR [95% CI]
Age 0.562 0.992 [0.965 1.019] 0.857 0.997 [0.965 1.03]
Gender 0.063 0.512 [0.253 1.037] 0.376 0.699 [0.316 1.546]
Resection type 0.066 0.511 [0.249 1.046] 0.002 0.235 [0.095 0.58]
FLAIRvol 0.381 1.004 [0.994 1.014] 0.404 1.005 [0.994 1.016]
CEvol 0.047 1.04 [1.001 1.08] 0.010 1.06 [1.014 1.108]
ADC-FLAIRvf 0.397 0.939 [0.811 1.087] 0.52 0.936 [0.766 1.145]
ADC-CEvf 0.804 1.011 [0.925 1.105] 0.932 0.995 [0.891 1.112]
ADC-FLAIR10% 0.384 1.001 [0.999 1.004] 0.624 1.001 [0.998 1.004]
ADC-CE10% 0.735 0.999 [0.997 1.002] 0.704 1.001 [0.998 1.003]
RSI-FLAIRvf 0.038 1.031 [1.002 1.061] 0.006 1.051 [1.015 1.089]
RSI-CEvf 0.12 1.03 [0.992 1.069] 0.021 1.048 [1.007 1.091]
RSI-FLAIR90% 0.092 1.522 [0.934 2.482] 0.028 2.041 [1.081 3.855]
RSI-CE90% 0.154 1.507 [0.858 2.649] 0.099 1.822 [0.893 3.716]
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Table 3
Results of multivariate CPH analyses of the continuous imaging metrics co-varied with resection type
Metrics PFS OS
p value HR [95% CI] p value HR [95% CI]
RSI-FLAIRvf 0.036 1.033 [1.002 1.064] 0.007 1.057 [1.015 1.100]
RSI-CEvf 0.258 1.022 [0.984 1.062] 0.183 1.028 [0.987 1.070]
RSI-FLAIR90% 0.097 1.535 [0.925 2.545] 0.043 2.111 [1.024 4.350]
RSI-CE90% 0.210 1.439 [0.814 1.543] 0.217 1.568 [0.767 3.203]
FLAIRvol 0.845 1.001 [0.990 1.012] 0.979 1.000 [0.989 1.011]
CEvol 0.165 1.029 [0.988 1.073] 0.063 1.044 [0.998 1.092]
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